HIV-1 subtype diversity among clinical specimens submitted for routine antiviral drug resistance testing in the United States

Diagn Microbiol Infect Dis. 2015 Nov;83(3):257-60. doi: 10.1016/j.diagmicrobio.2015.07.014. Epub 2015 Jul 26.

Abstract

Diversity of human immunodeficiency virus type 1 (HIV-1) has important implications for the diagnosis, treatment, and management of HIV-1-infected individuals. HIV-1 pol sequences from 3895 clinical plasma specimens collected in the United States over a 1-year period and submitted for routine HIV-1 genotypic drug resistance testing were retrospectively analyzed for HIV-1 subtype. Of these 3895 HIV-1 sequences, 207 (5.31%) were determined to be non-B subtypes (including recombinant forms). Among individual states, the percentage of non-B subtypes ranged from 0% (12 states) to 28.57% in South Dakota, with 7 states having percentages of >10%. All 4 states with the highest percentages of non-B subtypes were located within the US West North Central region: Minnesota, 11.82%; Iowa, 15.38%; North Dakota, 25.00%; and South Dakota, 28.57%. Reasons for the unexpectedly wide diversity of HIV-1 subtypes present in multiple states located in the West North Central region of the United States remain to be determined.

Keywords: HIV-1 strain diversity; HIV-1 subtypes.

MeSH terms

  • Drug Resistance, Viral
  • Female
  • Genotype*
  • Genotyping Techniques
  • HIV Infections / epidemiology
  • HIV Infections / virology*
  • HIV-1 / classification*
  • HIV-1 / genetics*
  • HIV-1 / isolation & purification
  • Humans
  • Male
  • Molecular Epidemiology
  • Retrospective Studies
  • Sequence Analysis, DNA
  • United States / epidemiology
  • pol Gene Products, Human Immunodeficiency Virus / genetics

Substances

  • pol Gene Products, Human Immunodeficiency Virus